Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

7.43
+0.01000.13%
Post-market: 7.600.1738+2.34%17:53 EDT
Volume:1.04M
Turnover:7.72M
Market Cap:490.48M
PE:-1.97
High:7.62
Open:7.58
Low:7.36
Close:7.42
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:0.63
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:6.83
PE(LYR):-1.98

Loading ...

Regenxbio - on Track to Initiate Bla for Rgx-202 in Q3 2026

THOMSON REUTERS
·
Jun 24

Dow Jones Top Company Headlines at 5 PM ET: Fatal Tesla Crash Into Texas Home Now Under Federal Safety Investigation | Domino's ...

Dow Jones
·
Jun 23

REGENXBIO Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 23

Dow Jones Top Company Headlines at 11 AM ET: Chevron Strikes Power Deal With Microsoft for West Texas AI Data Center | AbbVie ...

Dow Jones
·
Jun 22

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

TIPRANKS
·
Jun 22

Regenxbio Inc : Leerink Partners Raises Target Price to $18 From $17

THOMSON REUTERS
·
Jun 22

H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX)

TIPRANKS
·
Jun 22

Regenxbio Inc : Baird Raises Target Price to $32 From $27

THOMSON REUTERS
·
Jun 22

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

Reuters
·
Jun 22

BRIEF-Regenxbio Aligns With FDA For Potential Accelerated Approval Of NAVSUNLI

Reuters
·
Jun 22

Regenxbio says FDA clears path for NAVSUNLI accelerated-approval BLA resubmission in Q3 2026

Reuters
·
Jun 22

Regenxbio Announces Alignment With FDA on Path Forward for Navsunli™ Bla Resubmission for Accelerated Approval; First Potential Gene Therapy for Mps Ii

THOMSON REUTERS
·
Jun 22

Regenxbio - to Resubmit Navsunli Bla in Q3 2026

THOMSON REUTERS
·
Jun 22

Regenxbio Inc: Expects Type a Meeting to Take Place in July and to Resubmit the Bla Rapidly Following the Meeting in Q3 2026-Spokesperson

THOMSON REUTERS
·
Jun 22

Regenxbio: We Aligned With FDA Regarding Next Steps Needed for Potential Accelerated Approval of Navsunli - Spokerperson

THOMSON REUTERS
·
Jun 22

BUZZ-Regenxbio rises after report FDA to reverse rejection of rare-disease gene therapy

Reuters
·
Jun 22

Regenxbio Shares Up on WSJ Report of FDA U-Turn on Company's Gene Therapy

Dow Jones
·
Jun 22

Regenxbio Shares up 11.2% Premarket After Report US FDA to Reverse Rejection of Co's Rare-Disease Drug

THOMSON REUTERS
·
Jun 22

Regenxbio up 25% after saying FDA will reverse rejection, consider application

TIPRANKS
·
Jun 22

BRIEF-FDA Will Reverse Rejection Of Third Rare-Disease Drug, Regenxbio Says- WSJ

Reuters
·
Jun 22